This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

This study has been terminated.
(Based on preliminary safety data.)
Sponsor:
Information provided by (Responsible Party):
Acceleron Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01099761
First received: April 2, 2010
Last updated: March 8, 2017
Last verified: March 2017
Results First Received: May 10, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: ACE-031 0.5 mg/kg q4wk
Biological: ACE-031 1.0 mg/kg q2wk
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ACE-031 0.5 mg/kg q4wk ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
ACE-031 1.0 mg/kg q2wk ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
ACE-031 ACE-03 2.5 mg/kg q4wk ACE-031 2.5 mg/kg q4wk: ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
Placebo Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.

Participant Flow:   Overall Study
    ACE-031 0.5 mg/kg q4wk   ACE-031 1.0 mg/kg q2wk   ACE-031 ACE-03 2.5 mg/kg q4wk   Placebo
STARTED   9   9   0 [1]   6 
COMPLETED   9   9   0   6 
NOT COMPLETED   0   0   0   0 
[1] Study terminated prior to enrolling cohort 3



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ACE-031 0.5 mg/kg q4wk ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
ACE-031 1.0 mg/kg q2wk ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
ACE-031 ACE-03 2.5 mg/kg q4wk ACE-031 2.5 mg/kg q4wk: ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
Placebo Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
Total Total of all reporting groups

Baseline Measures
   ACE-031 0.5 mg/kg q4wk   ACE-031 1.0 mg/kg q2wk   ACE-031 ACE-03 2.5 mg/kg q4wk   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 9   9   0   6   24 
Age 
[Units: Participants]
Count of Participants
         
<=18 years      9 100.0%      9 100.0%         6 100.0%      24 100.0% 
Between 18 and 65 years      0   0.0%      0   0.0%         0   0.0%      0   0.0% 
>=65 years      0   0.0%      0   0.0%         0   0.0%      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
         
Female      0   0.0%      0   0.0%         0   0.0%      0   0.0% 
Male      9 100.0%      9 100.0%         6 100.0%      24 100.0% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
         
Hispanic or Latino      0   0.0%      0   0.0%         0   0.0%      0   0.0% 
Not Hispanic or Latino      9 100.0%      9 100.0%         6 100.0%      24 100.0% 
Unknown or Not Reported      0   0.0%      0   0.0%         0   0.0%      0   0.0% 
Region of Enrollment 
[Units: Participants]
         
Canada   9   9      6   24 
Able to ambulate 10 meters in < 12 seconds 
[Units: Participants]
 9   9      6   24 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Subjects With Adverse Reactions.   [ Time Frame: From treatment initiation to End-of-Study Visit, approximately 24 weeks later ]

2.  Primary:   Number of Subjects With Clinical Laboratory Adverse Reactions.   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

3.  Secondary:   Percent Change in Total Lean Body Mass by DXA Scan.   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

4.  Secondary:   Percent Change in Lumbar Spine Bone Mineral Density by DXA Scan.   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

5.  Secondary:   Percent Change in Muscle Strength Score by Hand-held Myometry.   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

6.  Secondary:   Change in Distance Traveled in 6 Minutes (Standardized 6-Minute-Walk Test).   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

7.  Secondary:   Change From Baseline in Time to Travel 10 Meters (Standardized 10-Meter-Walk/Run Test).   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

8.  Secondary:   Change in Pulmonary Function Tests (FVC)   [ Time Frame: Baseline to End-of-Study Visit, approximately 24 weeks later. ]

9.  Secondary:   Change in Pulmonary Function Test (MIP)   [ Time Frame: Baseline to End-of-Study Visit. approximately 24 weeks ]

10.  Secondary:   Change in Pulmonary Function Test (MEP)   [ Time Frame: Baseline to End-of-Stuidy Visit, approximately 24 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Kenneth Attie
Organization: Acceleron Pharma
phone: 617-649-9200 ext 350
e-mail: kattie@xlrn.com



Responsible Party: Acceleron Pharma, Inc.
ClinicalTrials.gov Identifier: NCT01099761     History of Changes
Other Study ID Numbers: A031-03
Study First Received: April 2, 2010
Results First Received: May 10, 2016
Last Updated: March 8, 2017